Drugs / Fixed-Dose Combination Albendazole/Ivermectin (FDC)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07661316 | Nov 2026 → Feb 2027 expected | ascariasis, hookworm infectious disease, strongyloidiasis, trichuriasis | Mundo Sano Foundation | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fixed-Dose Combination Albendazole/Ivermectin (FDC) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07661316 ↗ |
| Route | Oral | “A single oral dose of a fixed-dose combination (FDC) tablet” NCT07661316 ↗ |